Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q2
$1.42M Buy
13,700
+10,300
+303% +$1.04M 0.01% 1665
2018
Q1
$335K Buy
+3,400
New +$321K ﹤0.01% 2961
2017
Q4
Sell
-29,800
Closed -$2.29M 4680
2017
Q3
$2.29M Buy
29,800
+26,200
+728% +$2M 0.01% 1271
2017
Q2
$280K Buy
+3,600
New +$258K ﹤0.01% 3057
2017
Q1
Sell
-12,200
Closed -$757K 4872
2016
Q4
$757K Sell
12,200
-6,100
-33% -$374K 0.01% 2131
2016
Q3
$1.19M Sell
18,300
-21,600
-54% -$1.44M 0.01% 1635
2016
Q2
$2.52M Buy
39,900
+12,800
+47% +$755K 0.02% 1072
2016
Q1
$1.57M Buy
27,100
+1,900
+8% +$108K 0.01% 1327
2015
Q4
$1.35M Sell
25,200
-18,500
-42% -$1.04M 0.01% 1674
2015
Q3
$2.23M Sell
43,700
-19,400
-31% -$1.04M 0.01% 1493
2015
Q2
$3.56M Sell
63,100
-22,700
-26% -$1.43M 0.02% 1062
2015
Q1
$6.16M Buy
85,800
+70,800
+472% +$4.6M 0.05% 568
2014
Q4
$841K Hold
15,000
0.01% 2102
2014
Q3
$739K Buy
+15,000
New +$764K 0.01% 2106
2014
Q2
Sell
-5,600
Closed -$250K 5046
2014
Q1
$250K Sell
5,600
-2,900
-34% -$130K ﹤0.01% 3215
2013
Q4
$400K Sell
8,500
-6,900
-45% -$349K ﹤0.01% 2882
2013
Q3
$407K Buy
15,400
+15,100
+5,033% +$733K ﹤0.01% 2990
2013
Q2
$14 Buy
+300
New +$14.2K ﹤0.01% 4725

Other funds holding RMD

PEAK6 Group's RMD Position: Q2 2018 in Review

PEAK6 Group increased its ResMed (RMD) stake by 19% in Q2 2018, buying an estimated $77.1K and bringing the position to 4,807 shares worth $498K. The position accounts for ﹤0.01% of the portfolio, ranked #2598.

PEAK6 Group first reported a position in RMD in Q3 2013 and has held it in 5 quarters since. The position peaked at $981K in Q4 2016. 465 funds tracked by Wall St. Rank hold RMD as of Q2 2018.

  • PEAK6 Group held 4,807 shares of ResMed worth $498K as of Q2 2018.
  • PEAK6 Group bought 762 ResMed shares in Q2 2018, an estimated $77.1K.
  • ResMed made up ﹤0.01% of PEAK6 Group's portfolio in Q2 2018, its #2598 holding.
  • PEAK6 Group first reported a position in ResMed in Q3 2013 and has held it in 5 quarters since.
  • PEAK6 Group's ResMed position peaked at $981K in Q4 2016.
  • 465 funds tracked by Wall St. Rank held ResMed as of Q2 2018.

Based on PEAK6 Group's 13F filing for Q2 2018, filed 15 Aug 2018.